Sparteine oxidation is practically abolished in quinidine‐treated patients

In eight patients a sparteine‐test was carried out immediately before and after 1 week of treatment with quinidine 600‐800 mg day‐1. Before treatment one patient was classified as a poor metaboliser (metabolic ratio: greater than or equal to 20), and seven patients as extensive metabolisers. During...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 22; no. 2; pp. 194 - 197
Main Authors Brinn, R., Brosen, K., Gram, LF, Haghfelt, T., Otton, SV
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.08.1986
Blackwell Science
Subjects
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Female
General pharmacology
Humans
Male
Medical sciences
Middle Aged
Oxidation-Reduction
Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions
Pharmacology. Drug treatments
Quinidine - adverse effects
Quinidine - therapeutic use
Sparteine - metabolism
Human
Cardiovascular disease
Pharmacogenetics
Pharmacokinetics
Antiarrhythmia agent
Polymorphism
Online AccessGet full text

Cover

More Information
Summary:In eight patients a sparteine‐test was carried out immediately before and after 1 week of treatment with quinidine 600‐800 mg day‐1. Before treatment one patient was classified as a poor metaboliser (metabolic ratio: greater than or equal to 20), and seven patients as extensive metabolisers. During quinidine treatment, the formation of sparteine metabolites (2‐ and 5‐dehydrosparteine) was practically abolished. Patients initially classified as extensive metabolisers thus exhibited the phenotype of poor metabolisers during quinidine treatment.
ISSN:0306-5251
1365-2125
DOI:10.1111/j.1365-2125.1986.tb05250.x